{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.2","upperLimit":"70.0","value":"60.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"101"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"DCR was defined as the percentage of participants with a confirmed overall response (CR and PR) or stable disease (SD) (non-CR/non-PD) lasting at least 6 months from the start of treatment, until the first PD or new anti-cancer therapy, per RECIST v1.1 as determined by ICR. CR: disappearance of all target and non-target lesions and no appearance of any new lesions. Any pathological lymph nodes (whether target or non-target) must have a reduction in the short axis to \\<10 mm. PR: complete disappearance or at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters, no new lesions, and no progression of non-target lesions. PD: progression of a target or non-target lesion or presence of a new lesion. SD: no change in target lesions to qualify for CR, PR, or PD.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with recurrent, advanced locoregional disease or distant metastatic disease who did not receive any prior chemotherapy received retifanlimab 500 milligrams (mg), administered by intravenous (IV) infusion over 60 minutes on Day 1 of each 28-day cycle (Q4W).","id":"OG000","title":"Chemotherapy: Naïve"},{"description":"Participants with disease not responding to prior chemotherapy received retifanlimab 500 mg, administered by IV infusion over 60 minutes on Day 1 Q4W.","id":"OG001","title":"Chemotherapy: Refractory"}],"paramType":"NUMBER","populationDescription":"Safety Evaluable Population. Analysis was based on the chemotherapy-naïve subset of the population. CIs were calculated based on the exact method for binomial distributions.","reportingStatus":"POSTED","timeFrame":"up to 57.1 months","title":"Disease Control Rate (DCR)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}